TTM Technologies: Buy Upgrade Meets Continued Overvaluation Concerns

What happened

TTM Technologies reported Q3 2025 results with adjusted operating margins improving ~510 bps year-over-year to ~17.4%, driven by strong demand in aerospace & defense and AI-related data-center computing. Seeking Alpha analysts upgraded the stock to Buy, noting a valuation correction to ~10.9x forward EV/EBITDA and significantly raised 2027 revenue and EPS outlooks. However, the stock has already surged 165% over the past year, trading near $67.63, and still trades at ~52x trailing earnings and ~23x trailing EV/EBITDA. The DeepValue master report maintains a Strong Sell, arguing that the equity price capitalizes an aggressively optimistic outcome and that an FCF-based DCF values the stock at only ~$6.73 per share. While fundamentals are improving, the market appears to have already priced in sustained high growth and margin expansion, leaving little margin of safety for value-oriented investors.

Implication

The Seeking Alpha upgrade highlights genuine operational improvement and a valuation reset relative to recent peaks, but the stock still trades at elevated multiples for a cyclical, capital-intensive PCB manufacturer. Even after the correction, EV/EBITDA remains well above sector median and the DCF gap is enormous, suggesting the market is extrapolating AI and defense tailwinds far into the future. Execution risks on new capacity ramps (Syracuse, Penang, Eau Claire), customer concentration, and historical FCF volatility are not adequately reflected in the current price. A disciplined investor should require a much lower entry price—perhaps near mid-cycle earnings multiples—before considering a long position. Until then, monitoring for sustained margin improvements and valuation compression is preferable to buying at current levels.

Thesis delta

The thesis shifts from a purely negative stance to one that acknowledges tangible improvements in margin structure and demand mix, but the core valuation concern remains. The stock is no longer as egregiously overvalued as when it traded at higher multiples, yet it still embeds optimistic assumptions that are not yet proven. The upgrade to Buy reflects a relative valuation argument against sector peers, but absolute valuation still offers insufficient downside protection.